← Browse by Condition
Medical Condition

recurrent myelodysplastic syndrome

Total Trials
3
Recruiting Now
3
Trial Phases
Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for recurrent myelodysplastic syndrome sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — recurrent myelodysplastic syndrome Clinical Trials

How many clinical trials are currently recruiting for recurrent myelodysplastic syndrome?
ClinicalMetric currently tracks 3 actively recruiting clinical trials for recurrent myelodysplastic syndrome, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 3. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for recurrent myelodysplastic syndrome?
recurrent myelodysplastic syndrome research spans Phase 1 (1 trial), Phase 2 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a recurrent myelodysplastic syndrome clinical trial?
Eligibility criteria for recurrent myelodysplastic syndrome trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Top Sponsors
M.D. Anderson Cancer Center 1 trial
Fred Hutchinson Cancer Center 1 trial
City of Hope Medical Center 1 trial

Recruiting Clinical Trials

NCT04239157 Phase 2
Recruiting
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Enrollment
76 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT04375631 Phase 1
Recruiting
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
Enrollment
120 pts
Location
United States
Sponsor
Fred Hutchinson Cancer Center
View Trial →
NCT07582172 Phase 2
Recruiting
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Enrollment
35 pts
Location
United States
Sponsor
City of Hope Medical Center
View Trial →

Related Conditions

refractory myelodysplastic syndrome (3) myelodysplastic syndrome (2) recurrent chronic myelomonocytic leukemia (2) refractory chronic myelomonocytic leukemia (2) recurrent acute myeloid leukemia (2) refractory acute myeloid leukemia (2) chronic myelomonocytic leukemia (1) refractory mixed phenotype acute leukemia (1) refractory acute leukemia of ambiguous lineage (1) refractory acute undifferentiated leukemia (1) acute myeloid leukemia with complex karyotype (1) myelodysplastic chronic myelomonocytic leukemia (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology